| Item type |
デフォルトアイテムタイプ_（フル）(1) |
| 公開日 |
2023-03-18 |
| タイトル |
|
|
タイトル |
Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti–Programmed Cell Death-1 Therapy in NSCLC |
|
言語 |
en |
| 作成者 |
Ohue, Yoshihiro
Kurose, Koji
Karasaki, Takahiro
Isobe, Midori
Yamaoka, Takaaki
Futami, Junichiro
Irei, Isao
Masuda, Takeshi
Fukuda, Masaaki
Kinoshita, Akitoshi
Matsushita, Hirokazu
Shimizu, Katsuhiko
Nakata, Masao
Hattori, Noboru
Yamaguchi, Hiroyuki
Fukuda, Minoru
Nozawa, Ryohei
Kakimi, Kazuhiro
Oka, Mikio
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利情報 |
|
|
権利情報 |
© 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/). |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Biomarker |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Anti–programmed death 1 therapy |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
NSCLC |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Cancer-testis antigen |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Serum antibody |
| 内容記述 |
|
|
内容記述 |
Introduction: Programmed cell death-1 (PD-1) inhibitors effectively treat NSCLC and prolong survival. Robust biomarkers for predicting clinical benefits of good response and long survival with anti–PD-1 therapy have yet to be identified; therefore, predictive biomarkers are needed to select patients with benefits. Methods: We conducted a prospective study to explore whether serum antibody against NY-ESO-1 and/or XAGE1 cancer-testis antigens predicted primarily good clinical response and secondarily long survival with anti–PD-1 therapy for NSCLC. The serum antibody was detected by enzyme-linked immunosorbent assay, and tumor immune microenvironment and mutation burden were analyzed by immunohistochemistry and next-generation sequencing. Results: In the discovery cohort (n ¼ 13), six antibodypositive NSCLC cases responded to anti–PD-1 therapy (two complete and four partial responses), whereas seven antibody-negative NSCLC cases did not. Antibody positivity was associated with good response and survival, regardless of tumor programmed death ligand 1 (PD-L1) expression, mutation burden, and CD8þ T-cell infiltration. In the validation cohort (n ¼ 75), 17 antibody-positive NSCLC cases responded well to anti–PD-1 therapy as compared with 58 negative NSCLC cases (objective response rate 65% versus 19%, p ¼ 0.0006) and showed significantly prolonged progression-free survival and overall survival. Antibody titers highly correlated with tumor reduction rates. In the multivariate analysis, response biomarkers were tumor programmed death ligand 1 expression and antibody positivity, and only antibody positivity was a significantly better predictive biomarker of progression-free survival (hazard ratio ¼ 0.4, p ¼ 0.01) and overall survival (hazard ratio ¼ 0.2, p ¼ 0.004). Conclusions: Our results suggest that NY-ESO-1 and/or XAGE1 serum antibodies are useful biomarkers for predicting clinical benefits in anti–PD-1 therapy for NSCLC and probably for other cancers. |
|
言語 |
en |
| 内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
This work was supported by grants from JSPS KAKENHI (15K09235, 16K18463, 16K21533, 18K15226, and 18K07306) to Drs. Oka, Ohue, and Kurose; by grants from the Takeda Science Foundation to Drs. Ohue and Kurose; by a grant from the Medical Research Encouragement Prize of The Japan Medical Association to Dr. Ohue; by a grant from the Okayama Health Foundation to Dr. Ohue; and by grants from Kawasaki Medical School to Drs. Oka, Ohue, and Kurose. Dr. Oka received collaborative research funds from the University of Tokyo and Thyas Co., Ltd. The Department of Immuno-Oncology is endowed by Pole Star Co., Ltd. |
| 出版者 |
|
|
出版者 |
International Association for the Study of Lung Cancer |
| 出版者 |
|
|
出版者 |
Elsevier |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1016/j.jtho.2019.08.008 |
| 関連情報 |
|
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
31449889 |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1016/j.jtho.2019.08.008 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1556-0864 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1556-1380 |
| 開始ページ |
|
|
開始ページ |
2071 |
| 書誌情報 |
Journal of Thoracic Oncology
Journal of Thoracic Oncology
巻 14,
号 12,
p. 2071-2083,
発行日 2019-12
|
| 旧ID |
48637 |
JThoracOncol_14_2071.pdf (889.0 KB)
